CVRdatabase
Menu

Novo Nordisk Denmark A/S

Public limited companyCVR 38180045København SActive

Novo Nordisk Denmark A/S is a public limited company, based in København S, active in wholesale of pharmaceutical goods and nursing supplies, founded in 2016. Net profit rose 38% from 2024 to 2025, ending at DKK 118.8m. Measured by gross profit, it ranks no. 5 of 232 companies in the industry in the database. Profit has grown three years in a row.

Follow
PDF reportCompare

Key figures · financial year 2025

RevenueDKK 2.5bn+5.8% vs. 2024
Net profitDKK 118.8m+37.9% vs. 2024
EquityDKK 134.6m+32.2% vs. 2024
Employees300latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Gross profit fell 12% (2024 → 2025), to DKK 497.5m.
  • Revenue rose 6% (2024 → 2025), to DKK 2.5bn.
  • Net profit rose 38% (2024 → 2025), to DKK 118.8m.
  • Equity rose 32% (2024 → 2025), to DKK 134.6m.

Employees

  • 10 fewer employees than a year earlier: 300 (07/2026) against 310 (07/2025).

Management and owners, last 24 months

  • New in management: Mads Wilhelm Øckenholt Larsen (director, 17/01/2025), Jeppe Theisen (board member, 06/03/2026) and David Marcus Svensson (board member, 06/03/2026) (+1).
  • Stepped down: Jeppe Theisen (director, 17/01/2025), Jonas Emil Kongshøj Larsen (chair of the board, 20/10/2026) and Malin Eva Maria Andreasen (board member, 06/03/2026) (+1).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

DKK 0DKK 20mDKK 40mDKK 60mDKK 80mDKK 100mDKK 120mDKK 140m202020212022202320242025
EquityNet profit
Financial figures for Novo Nordisk Denmark A/S
202020212022202320242025Change
Revenue330,145373,940509,9202,017,3462,367,7512,504,841+5.8%
Gross profit276,132311,891333,173473,479564,362497,538−11.8%
Operating profit (EBIT)28,20830,23242,630101,020101,371145,788+43.8%
Profit before tax28,00828,64544,034107,912115,703156,504+35.3%
Net profit21,27821,40533,54881,99886,129118,803+37.9%
Total assets584,971283,420446,7341,184,0041,056,0041,375,553+30.3%
Equity36,58736,99349,14097,638101,767134,570+32.2%
Liabilities545,785208,566359,5221,041,468941,7551,231,911+30.8%
Cash and cash equivalents326,474––––––
Average number of employees152176200236294299+1.7%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report.

Download the figures as CSV · free with an account, amounts in whole DKK

DKK 0DKK 100mDKK 200mDKK 300mDKK 400mDKK 500mDKK 600m202020212022202320242025
Gross profitMedian, the industry (232 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Low equity ratio

    Equity makes up 10% of total assets in 2025.

    How is this calculated?

    Equity ÷ total assets is below 10% in the latest annual report. Banks, insurers and some industries naturally have a low ratio.

  • Profit for five years in a row

    Net result has been positive in 2021–2025.

    How is this calculated?

    Net result is positive in the five latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Novo Nordisk Denmark A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202525/06/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202430/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202327/05/2024The companyPDFXBRL
202201/01/2022 – 31/12/202216/06/2023The companyPDFXBRL
202101/01/2021 – 31/12/202117/05/2022The companyPDFXBRL
202001/01/2020 – 31/12/202015/06/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
05010015020025030035008/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

232 companies in the database

Comparison with the other companies in wholesale of pharmaceutical goods and nursing supplies based on the latest financial year.

Gross profitDKK 497.5mNo. 5 of 232
Better than 98% of the companies in the industry
EquityDKK 134.6mNo. 19 of 232
Better than 92% of the companies in the industry
Number of employees300No. 9 of 232
Better than 97% of the companies in the industry

Industry median: gross profit DKK 11.2m, net profit DKK 1.8m, equity DKK 9.6m, 9 employees.

DKK 100kDKK 1.4mDKK 19.1mDKK 263.2mDKK 1.5bnHere
Distribution of gross profit for 225 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 200–499 employees796 companies in the comparison
No. 57of 763
Better than 93%
No. 335of 796
Better than 58%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 58of 33,588
Better than 100%
No. 547of 33,687
Better than 98%
All companies of type A/S18,025 companies in the comparison
No. 289of 17,786
Better than 98%
No. 1,871of 18,024
Better than 90%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Wholesale of pharmaceutical goods and nursing supplies
Gross profit
  1. Novo Nordisk Denmark A/SDKK 497.5m
  2. Ambu A/SDKK 3.6bn
  3. Stada Nordic ApSDKK 687m
Net profit
  1. Novo Nordisk Denmark A/SDKK 118.8m
  2. Ambu A/SDKK 609m
  3. Stada Nordic ApSDKK 54.6m
Equity
  1. Novo Nordisk Denmark A/SDKK 134.6m
  2. Ambu A/SDKK 6bn
  3. Stada Nordic ApSDKK 346.3m
Employees
  1. Novo Nordisk Denmark A/S300
  2. Ambu A/S619
  3. Stada Nordic ApS51

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Novo Nordisk Region Europe A/S100%
Novo Nordisk Denmark A/S

Management

4 active registrations

Executive management

Executive management at Novo Nordisk Denmark A/S
NameRoleAppointed
Mads Wilhelm Øckenholt LarsenDirector17/01/2025

Board of directors

Board of directors at Novo Nordisk Denmark A/S
NameRoleAppointed
Jeppe TheisenBoard member06/03/2026
David Marcus SvenssonBoard member06/03/2026
Mark Iain HickenChair of the board20/10/2026
Founders
Novo Nordisk Region Europe A/S
Former management (21)
Former management at Novo Nordisk Denmark A/S
NameRoleAppointedResigned
Mads Veggerby LaustenDirector14/11/201601/01/2018
Ole Falvig RamsbyBoard member14/11/201614/09/2017
Jesper BrandgaardBoard member14/11/201615/09/2017
Lars Fruergaard JørgensenBoard member14/11/201615/09/2017
Karsten Munk KnudsenDirector14/11/201615/09/2017
Ole Falvig RamsbyChair of the board15/09/201701/10/2018
Karsten Munk KnudsenBoard member15/09/201730/09/2018
Matt Joseph ReganBoard member15/09/201730/09/2019
Steffen Hillebrandt ThejlsDirector01/01/201815/05/2018
Morten Berger EngelundDirector15/05/201830/11/2019
Tomas HaagenBoard member01/10/201802/04/2024
Karsten Munk KnudsenChair of the board01/10/201801/10/2019
Mads Veggerby LaustenBoard member01/10/201901/04/2020
Matt Joseph ReganChair of the board01/10/201901/04/2020
Kasper Bødker MejlvangDirector01/12/201926/10/2022
Frederik KierChair of the board01/04/202026/10/2022
Morten Berger EngelundBoard member01/04/202002/04/2024
Jeppe TheisenDirector26/10/202217/01/2025
Jonas Emil Kongshøj LarsenChair of the board26/10/202220/10/2026
Malin Eva Maria AndreasenBoard member02/04/202406/03/2026
Anders Rytter MikkelsenBoard member02/04/202406/03/2026

Signing rule: Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af  et bestyrelsesmedlem i forening med en direktør

Address and production units

2 active production units

Kay Fiskers Plads 10
2300 København S

København Municipality · Postcode 2300

Other companies at the address (8)

Open in OpenStreetMap
Production units
Production unitAddressEmployeesP number
Novo Nordisk Denmark A/SKay Fiskers Plads 10, 2300 København S2961028867499
Novo Nordisk Denmark A/SKay Fiskers Plads 10, 2300 København S11021921986

Purpose

Selskabets formål er at markedsføre, promovere, importere, sælge og distribuere farmaceutiske og medicinske produkter, repræsentation af selskaber, supporterende services og forretningsassistance til interessenter i Europa, rådgivning og services i forbindelse med registrering af farmaceutiske produkter, forskning og udvikling af farmaceutiske produkter, kliniske forsøg, samt anden hertil knyttet virksomhed der ikke er forbudt ved lov. Selskabets formål er tillige at understøtte Novo Nordisk A/S farmaceutiske aktivitet. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.

The purpose is quoted from the register in Danish.

Changes year by year

62 registered events
20267 changesmanagement 6 · accounts 1
  • Mark Iain Hicken appointed chair of the board
  • Jonas Emil Kongshøj Larsen stepped down as chair of the board
  • Annual report for 2025 published
  • David Marcus Svensson appointed board member
  • Jeppe Theisen appointed board member
  • Malin Eva Maria Andreasen stepped down as board member
  • Anders Rytter Mikkelsen stepped down as board member
20253 changesaccounts 1 · management 2
  • Annual report for 2024 published
  • Mads Wilhelm Øckenholt Larsen appointed director
  • Jeppe Theisen stepped down as director
20246 changesaddress 1 · accounts 1 · management 4
  • Moved to Kay Fiskers Plads 10, 2300 København S
  • Annual report for 2023 published
  • Malin Eva Maria Andreasen appointed board member
  • Anders Rytter Mikkelsen appointed board member
  • Morten Berger Engelund stepped down as board member
  • Tomas Haagen stepped down as board member
20232 changesaccounts 1 · address 1
  • Annual report for 2022 published
  • Moved to Kay Fiskers Plads 10, 7, 2300 København S
20226 changesaddress 1 · management 4 · accounts 1
  • Moved to Kay Fiskers Plads 10, 2300 København S
  • Jonas Emil Kongshøj Larsen appointed chair of the board
  • Jeppe Theisen appointed director
  • Frederik Kier stepped down as chair of the board
  • Kasper Bødker Mejlvang stepped down as director
  • Annual report for 2021 published
20211 changeaccounts 1
  • Annual report for 2020 published
20204 changesmanagement 4
  • Frederik Kier appointed chair of the board
  • Morten Berger Engelund appointed board member
  • Mads Veggerby Lausten stepped down as board member
  • Matt Joseph Regan stepped down as chair of the board
20197 changesmanagement 6 · name 1
  • Kasper Bødker Mejlvang appointed director
  • Morten Berger Engelund stepped down as director
  • Name changed from Novo Nordisk Region Europe Pharmaceuticals A/S to Novo Nordisk Denmark A/S
  • Mads Veggerby Lausten appointed board member
  • Matt Joseph Regan appointed chair of the board
  • Karsten Munk Knudsen stepped down as chair of the board
  • Matt Joseph Regan stepped down as board member
20189 changesaddress 1 · management 8
  • Moved to Ørestads Boulevard 108, 2300 København S
  • Tomas Haagen appointed board member
  • Karsten Munk Knudsen appointed chair of the board
  • Ole Falvig Ramsby stepped down as chair of the board
  • Karsten Munk Knudsen stepped down as board member
  • Morten Berger Engelund appointed director
  • Steffen Hillebrandt Thejls stepped down as director
  • Steffen Hillebrandt Thejls appointed director
  • Mads Veggerby Lausten stepped down as director
20179 changesmanagement 7 · address 1 · industry 1
  • Ole Falvig Ramsby appointed chair of the board
  • Matt Joseph Regan appointed board member
  • Karsten Munk Knudsen appointed board member
  • Karsten Munk Knudsen stepped down as director
  • Lars Fruergaard Jørgensen stepped down as board member
  • Jesper Brandgaard stepped down as board member
  • Ole Falvig Ramsby stepped down as board member
  • Moved to Ørestads Boulevard 108, 2300 København S
  • Industry changed to Wholesale of pharmaceutical goods and nursing supplies (464610)
20168 changesaddress 1 · founded 1 · management 5 · ownership 1
  • Moved to Arne Jacobsens Allé 17, 9, 2300 København S
  • Registered as Novo Nordisk Region Europe Pharmaceuticals A/S
  • Mads Veggerby Lausten appointed director
  • Karsten Munk Knudsen appointed director
  • Lars Fruergaard Jørgensen appointed board member
  • Jesper Brandgaard appointed board member
  • Ole Falvig Ramsby appointed board member
  • NOVO NORDISK REGION EUROPE A/S registered as owner (100%)

Related companies

Same industry in København

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 23/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction